Lim et al. confirmed the efficacy of IVIG during therapies with daratumumab and anti-BCMA bi-specific antibodies in reducing by 40% the rate of all-grade infections per year, providing important findings for the application of IgRT for MM patients in combination with novel immunotherapies including bi-specific antibodies [98,104]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.